Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
Status:
Completed
Trial end date:
2013-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works in treating
patients with stage IV kidney cancer.